Mette Husbyn

CTO at Lytix Biopharma, Norway

Speaker

Dr. Husbyn earned her doctorate from the Medical Faculty of the University of Oslo in 2003, specializing in peptide chemistry, and brings over 16 years of experience at GE Healthcare, where she held various scientific and managerial roles covering all aspects of CMC, from pre-clinical and early clinical phases to commercial products.

Following her tenure at GEHC, Dr. Husbyn served as Head of CMC at Lytix Biopharma from 2012 to 2017, where she oversaw all CMC activities and established robust processes to enhance drug development.

Until February this year, she held the position of CTO at Nykode Therapeutics, leading a team of 32 professionals focused on strategic partner selection, biologics process development and manufacturing, and regulatory interactions across the US and Europe.

Currently she is the CTO of Lytix Biopharma, a Norwegian Biotech company, focusing on oncolytic peptides and small molecules.